368 related articles for article (PubMed ID: 33789687)
1. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
Nero C; Vizzielli G; Lorusso D; Cesari E; Daniele G; Loverro M; Scambia G; Sette C
J Exp Clin Cancer Res; 2021 Mar; 40(1):116. PubMed ID: 33789687
[TBL] [Abstract][Full Text] [Related]
2. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
Chen H; Gotimer K; De Souza C; Tepper CG; Karnezis AN; Leiserowitz GS; Chien J; Smith LH
Gynecol Oncol; 2020 Jun; 157(3):783-792. PubMed ID: 32253045
[TBL] [Abstract][Full Text] [Related]
3. Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models.
Maenhoudt N; Defraye C; Boretto M; Jan Z; Heremans R; Boeckx B; Hermans F; Arijs I; Cox B; Van Nieuwenhuysen E; Vergote I; Van Rompuy AS; Lambrechts D; Timmerman D; Vankelecom H
Stem Cell Reports; 2020 Apr; 14(4):717-729. PubMed ID: 32243841
[TBL] [Abstract][Full Text] [Related]
4. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
Pamarthy S; Sabaawy HE
Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
[TBL] [Abstract][Full Text] [Related]
5. High-grade serous ovarian carcinoma organoids as models of chromosomal instability.
Vias M; Morrill Gavarró L; Sauer CM; Sanders DA; Piskorz AM; Couturier DL; Ballereau S; Hernando B; Schneider MP; Hall J; Correia-Martins F; Markowetz F; Macintyre G; Brenton JD
Elife; 2023 May; 12():. PubMed ID: 37166279
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract][Full Text] [Related]
7. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids.
Graham O; Rodriguez J; van Biljon L; Fashemi B; Graham E; Fuh K; Khabele D; Mullen M
J Vis Exp; 2023 Jan; (191):. PubMed ID: 36688549
[TBL] [Abstract][Full Text] [Related]
8. Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine.
Spagnol G; Sensi F; De Tommasi O; Marchetti M; Bonaldo G; Xhindoli L; Noventa M; Agostini M; Tozzi R; Saccardi C
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046719
[TBL] [Abstract][Full Text] [Related]
9. Patient-derived organoids in ovarian cancer: Current research and its clinical relevance.
Kumar S; Raina M; Tankay K; Ingle GM
Biochem Pharmacol; 2023 Jul; 213():115589. PubMed ID: 37196684
[TBL] [Abstract][Full Text] [Related]
10. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
[TBL] [Abstract][Full Text] [Related]
11. 3D dynamic cultures of HGSOC organoids to model innovative and standard therapies.
Cavarzerani E; Caligiuri I; Bartoletti M; Canzonieri V; Rizzolio F
Front Bioeng Biotechnol; 2023; 11():1135374. PubMed ID: 37143603
[TBL] [Abstract][Full Text] [Related]
12. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
13. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
[TBL] [Abstract][Full Text] [Related]
14. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
15. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
[TBL] [Abstract][Full Text] [Related]
16. High-throughput approaches for precision medicine in high-grade serous ovarian cancer.
Govindarajan M; Wohlmuth C; Waas M; Bernardini MQ; Kislinger T
J Hematol Oncol; 2020 Oct; 13(1):134. PubMed ID: 33036656
[TBL] [Abstract][Full Text] [Related]
17. Novel Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Uncovered by Data-Independent Acquisition Mass Spectrometry.
Huh S; Kang C; Park JE; Nam D; Kim SI; Seol A; Choi K; Hwang D; Yu MH; Chung HH; Lee SW; Kang UB
J Proteome Res; 2022 Sep; 21(9):2146-2159. PubMed ID: 35939567
[TBL] [Abstract][Full Text] [Related]
18. Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas.
Arias-Diaz AE; Ferreiro-Pantin M; Barbazan J; Perez-Beliz E; Ruiz-Bañobre J; Casas-Arozamena C; Muinelo-Romay L; Lopez-Lopez R; Vilar A; Curiel T; Abal M
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686015
[TBL] [Abstract][Full Text] [Related]
19. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
Tao M; Wu X
J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
[TBL] [Abstract][Full Text] [Related]
20. KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer.
De Donato M; Babini G; Mozzetti S; Buttarelli M; Ciucci A; Arduini G; De Rosa MC; Scambia G; Gallo D
J Exp Clin Cancer Res; 2020 Nov; 39(1):265. PubMed ID: 33250051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
